EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy

Semaglutide and tirzepatide should be considered the first-choice pharmacologic treatments for individuals living with obesity and most related complications, according to a new framework from the European Association for the Study of Obesity…